Igf2 ligand dependency of Pten +- developmental and tumour phenotypes in the mouse

Oncogene

Volumn 31, Issue 31, 2012, Pages 3635-3646

  Church, D N ^a   Phillips, B R ^b   Stuckey, D J ^c,e   Barnes, D J ^a   Buffa, F M ^d   Manek, S ^b   Clarke, K ^c   Harris, A L ^d   Carter, E J ^a   Hassan, A B ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Cowden syndrome; IGF2; imprinting; mammary gland; placenta; PTEN

Indexed keywords

MICRORNA; MICRORNA 483; MICRORNA 675; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SOMATOMEDIN B; UNCLASSIFIED DRUG;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CANCER CELL; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DESENSITIZATION; EMBRYO; EMBRYO DEVELOPMENT; FEMALE; GENE; GENE EXPRESSION; GENE INTERACTION; GENE LOSS; HEART VENTRICLE HYPERTROPHY; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IGF2 GENE; LETHALITY; LIFESPAN; MOUSE; NONHUMAN; PHENOTYPE; PLACENTA; PLACENTA DEVELOPMENT; PRIORITY JOURNAL; PTEN TUMOR SUPPRESSOR GENE; SURVIVAL; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ANIMALS; CARCINOMA; CARDIOMEGALY; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR II; LONGEVITY; MALE; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED C57BL; PLACENTA; PREGNANCY; PTEN PHOSPHOHYDROLASE; SEX FACTORS;

MURINAE;

EID: 84864884002     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.526     Document Type: Article

References (51)

1. Alimonti A, Carracedo A, Clohessy JG, Trotman LC, Nardella C, Egia A et al. (2010). Subtle variations in Pten dose determine cancer susceptibility. Nat Genet: United States 42: 454-458.
2. Bartolomei MS, Zemel S, Tilghman SM. (1991). Parental imprinting of the mouse H19 gene. Nature 351: 153-155.
3. Bates P, Fisher R, Ward A, Richardson L, Hill DJ, Graham CF. (1995). Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II). Br J Cancer 72: 1189-1193.
4. Bayascas JR, Leslie NR, Parsons R, Fleming S, Alessi DR. (2005). Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN( +-) mice. Current Biology: CB 15: 1839-1846.
5. Bell AC, Felsenfeld G. (2000). Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene. Nature 405: 482-485.
6. Burns JL, Hassan AB. (2001). Cell survival and proliferation are modified by insulin-like growth factor 2 between days 9 and 10 of mouse gestation. Development 128: 3819-3830.
7. Camps C, Buffa FM, Colella S, Moore J, Sotiriou C, Sheldon H et al. (2008). hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res: United States 14: 1340-1348.
8. Carracedo A, Pandolfi PP. (2008). The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 27: 5527-5541.
9. Carter AM, Nygard K, Mazzuca DM, Han VK. (2006). The expression of insulin-like growth factor and insulin-like growth factor binding protein mRNAs in mouse placenta. Placenta 27: 278-290.
10. Chen ML, Xu PZ, Peng XD, Chen WS, Guzman G, Yang X et al. (2006). The deficiency of Akt1 is sufficient to suppress tumor development in Pten + -mice. Genes Dev 20: 1569-1574.
11. Christofori G, Naik P, Hanahan D. (1994). A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature 369: 414-418.
12. Coan PM, Conroy N, Burton GJ, Ferguson-Smith AC. (2006). Origin and characteristics of glycogen cells in the developing murine placenta. Dev Dyn 235: 3280-3294.
13. Corcoran RB, Bachar Raveh T, Barakat MT, Lee EY, Scott MP. (2008). Insulin-like growth factor 2 is required for progression to advanced medulloblastoma in patched1 heterozygous mice. Cancer Res 68: 8788-8795.
14. Crackower MA. (2002). Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 110: 737-749.
15. Cui H, Onyango P, Brandenburg S, Wu Y, Hsieh CL, Feinberg AP. (2002). Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Res 62: 6442-6446.
16. Cully M, Elia A, Ong SH, Stambolic V, Pawson T, Tsao MS et al. (2004). grb2 heterozygosity rescues embryonic lethality but not tumorigenesis in pten +-mice. Proc Natl Acad Sci USA 101: 15358-15363.
17. DeChiara TM, Efstratiadis A, Robertson EJ. (1990). A growthdeficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature 345: 78-80.
18. DeChiara TM, Robertson EJ, Efstratiadis A. (1991). Parental imprinting of the mouse insulin-like growth factor II gene. Cell 64: 849-859.
19. Di Cristofano A, De Acetis M, Koff A, Cordon-Cardo C, Pandolfi PP. (2001). Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 27: 222-224.
20. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. (1998). Pten is essential for embryonic development and tumour suppression. Nat Genet 19: 348-355.
21. Esquiliano DR, Guo W, Liang L, Dikkes P, Lopez MF. (2009). Placental glycogen stores are increased in mice with H19 null mutations but not in those with insulin or IGF type 1 receptor mutations. Placenta 30: 693-699.
22. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H et al. (2008). Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14: 518-527.
23. Foulstone E, Prince S, Zaccheo O, Burns JL, Harper J, Jacobs C et al. (2005). Insulin-like growth factor ligands, receptors, and binding proteins in cancer. J Pathol 205: 145-153.
24. Frank D, Fortino W, Clark L, Musalo R, Wang W, Saxena A et al. (2002). Placental overgrowth in mice lacking the imprinted gene Ipl. Proc Natl Acad Sci USA 99: 7490-7495.
25. Gabory A, Ripoche MA, Le Digarcher A, Watrin F, Ziyyat A, Forne T et al. (2009). H19 acts as a transregulator of the imprinted gene network controlling growth in mice. Development 136: 3413-3421.
26. Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, Sheen J-H et al. (2009). mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 15: 148-159.
27. Harper J, Burns JL, Foulstone EJ, Pignatelli M, Zaina S, Hassan AB. (2006). Soluble IGF2 receptor rescues Apc(Min/+) intestinal adenoma progression induced by Igf2 loss of imprinting. Cancer Res 66: 1940-1948.
28. Hassan AB, Howell JA. (2000). Insulin-like growth factor II supply modifies growth of intestinal adenoma in Apc(Min/+) mice. Cancer Res 60: 1070-1076.
29. Lackey J, Barnett J, Davidson L, Batty IH, Leslie NR, Downes CP. (2007). Loss of PTEN selectively desensitizes upstream IGF1 and insulin signaling. Oncogene 26: 7132-7142.
30. Leighton PA, Ingram RS, Eggenschwiler J, Efstratiadis A, Tilghman SM. (1995). Disruption of imprinting caused by deletion of the H19 gene region in mice. Nature 375: 34-39.
31. Li P, Cavallero S, Gu Y, Chen TH, Hughes J, Hassan AB et al. (2011). IGF signaling directs ventricular cardiomyocyte proliferation during embryonic heart development. Development 138: 1795-1805.
32. Liu YF, Paz K, Herschkovitz A, Alt A, Tennenbaum T, Sampson SR et al. (2001). Insulin stimulates PKCzeta-mediated phosphorylation of insulin receptor substrate-1 (IRS-1). A self-attenuated mechanism to negatively regulate the function of IRS proteins. J Biol Chem 276: 14459-14465.
33. Lopez MF, Dikkes P, Zurakowski D, Villa-Komaroff L. (1996). Insulin-like growth factor II affects the appearance and glycogen content of glycogen cells in the murine placenta. Endocrinology 137: 2100-2108.
34. Ma L, Teruya-Feldstein J, Behrendt N, Chen Z, Noda T, Hino O et al. (2005). Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. Genes Dev 19: 1779-1786.
35. Manning BD. (2005). Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev 19: 1773-1778.
36. Moorehead RA, Hojilla CV, De Belle I, Wood GA, Fata JE, Adamson ED et al. (2003). Insulin-like growth factor-II regulates PTEN expression in the mammary gland. J Biol Chem 278: 50422-50427.
37. Perks CM, Vernon EG, Rosendahl AH, Tonge D, Holly JM. (2007). IGF-II and IGFBP-2 differentially regulate PTEN in human breast cancer cells. Oncogene 26: 5966-5972.
38. Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM et al. (1999). Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 96: 1563-1568.
39. Ravichandran LV, Esposito DL, Chen J, Quon MJ. (2001). Protein kinase C-zeta phosphorylates insulin receptor substrate-1 and impairs its ability to activate phosphatidylinositol 3-kinase in response to insulin. J Biol Chem 276: 3543-3549.
40. Reardon W, Zhou XP, Eng CC. (2001). A novel germline mutation of the PTEN gene in a patient with macrocephaly, ventricular dilatation, and features of VATER association. J Med Genet 38: 820-823.
41. Sakatani T, Kaneda A, Iacobuzio-Donahue CA, Carter MG, de Boom Witzel S, Okano H et al. (2005). Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. Science 307: 1976-1978.
42. Singer C, Rasmussen A, Smith HS, Lippman ME, Lynch HT, Cullen KJ. (1995). Malignant breast epithelium selects for insulin-like growth factor II expression in breast stroma: evidence for paracrine function. Cancer Res 55: 2448-2454.
43. Soroceanu L, Kharbanda S, Chen R, Soriano RH, Aldape K, Misra A et al. (2007). Identification of IGF2 signaling through phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma. Proc Natl Acad Sci USA 104: 3466-3471.
44. Trimboli AJ, Cantemir-Stone CZ, Li F, Wallace JA, Merchant A, Creasap N et al. (2009). Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature 461: 1084-1091.
45. Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pandolfi PP. (2006). Identification of a tumour suppressor network opposing nuclear Akt function. Nature 441: 523-527.
46. Tsang WP, Ng EK, Ng SS, Jin H, Yu J, Sung JJ et al. (2010). Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. Carcinogenesis 31: 350-358.
47. van Roozendaal CE, Gillis AJ, Klijn JG, van Ooijen B, Claassen CJ, Eggermont AM et al. (1998). Loss of imprinting of IGF2 and not H19 in breast cancer, adjacent normal tissue and derived fibroblast cultures. FEBS Lett 437: 107-111.
48. Veronese A, Lupini L, Consiglio J, Visone R, Ferracin M, Fornari F et al. (2010). Oncogenic role of miR-483-3p at the IGF2/483 locus. Cancer Res 70: 3140-3149.
49. Wang H, Karikomi M, Naidu S, Rajmohan R, Caserta E, Chen HZ et al. (2010). Allele-specific tumor spectrum in pten knockin mice. Proc Natl Acad Sci USA: United States 107: 5142-5147.
50. Yang ZZ, Tschopp O, Hemmings-Mieszczak M, Feng J, Brodbeck D, Perentes E et al. (2003). Protein kinase B alpha/Akt1 regulates placental development and fetal growth. J Biol Chem 278: 32124-32131.
51. Yoshimizu T, Miroglio A, Ripoche MA, Gabory A, Vernucci M, Riccio A et al. (2008). The H19 locus acts in vivo as a tumor suppressor. Proc Natl Acad Sci USA 105: 12417-12422.